更新于：2024-11-01

Headache caused by drug

药物引起的头痛

更新于：2024-11-01

基本信息

别名

Drug induced headache、Drug-induced headache、Headache caused by drug

+ [8]

简介-

关联

项与药物引起的头痛相关的临床试验

IRCT20141023019640N3 / Recruiting临床3期IIT

The effect of Ketamine infusion versus prednisolone on patients with medication overuse headache

开始日期2024-06-21

申办/合作机构

Tehran University of Medical Sciences

JPRN-UMIN000052834 / RecruitingIIT

Electrical pain thresholds about the upper and lower limbs of headache patients - Electrical pain thresholds about the upper and lower limbs of headache patients

开始日期2023-10-01

申办/合作机构-

DRKS00025961 / RecruitingN/AIIT

Prevention of Medication Overuse (MO) and Medication Overuse Headache (MOH): A randomized, controlled, parallel, multicenter, prospective trial using a mobile application software - MOH

开始日期2022-03-08

申办/合作机构-

100 项与药物引起的头痛相关的临床结果

登录后查看更多信息

100 项与药物引起的头痛相关的转化医学

登录后查看更多信息

0 项与药物引起的头痛相关的专利（医药）

登录后查看更多信息

257

项与药物引起的头痛相关的文献（医药）

2024-04-01·Journal of Affective Disorders

A comparison between psilocybin and esketamine in treatment-resistant depression using number needed to treat (NNT): A systematic review

Review

作者: d'Andrea, Giacomo ; Cao, Bing ; Kwan, Angela T H ; Ho, Roger ; Teopiz, Kayla M ; Di Vincenzo, Joshua D ; Wong, Sabrina ; Le, Gia Han ; Rosenblat, Joshua D ; Meshkat, Shakila ; McIntyre, Roger S

BACKGROUNDInadequate outcomes with monoamine-based treatments in depressive disorders are common and provide the impetus for mechanistically-novel treatments. Esketamine is a proven treatment recently approved for adults with Treatment-Resistant Depression (TRD) while psilocybin is an investigational treatment. Translation of the clinical meaningfulness for these foregoing agents in adults with TRD is required. Herein we evaluate the Number Needed to Treat (NNT) and Harm (NNH) of esketamine and psilocybin in adults with TRD.METHODSWe conducted a systematic review of randomized controlled trials, comparing the clinical efficacy of oral psilocybin to the co-commencement of intranasal esketamine with an oral antidepressant in adults with TRD.RESULTS25 mg psilocybin had a significant reduction in depressive symptoms at 21-days post-dose, the NNT was 5 [95 % CI = 3.1, 18.5]. Psilocybin-induced nausea had a significant NNH = 5. Fixed-dosed esketamine at 56 mg and 84 mg had a significant effect at 28-days post-dose, (NNT of 7 [95 % CI_56mg = 3.5, 46.7], [95 % CI_84mg = 3.6, 142.2]). Esketamine-induced headache, nausea, dizziness, and dissociation had NNHs <10.LIMITATIONSThe preliminary results may only reflect a small portion of the patient population. These results require replication and longer term studies investigating maintenance therapy.CONCLUSIONRelatively few pharmacologic agents are proven safe and effective in adults with TRD. NNT estimates for investigational psilocybin and esketamine in TRD indicate clinical meaningfulness. The NNH profile for both aforementioned agents is clinically acceptable. Our results underscore the clinical relevance of these treatment options in adults with TRD.

2024-02-01·Cephalalgia

Health care resource utilization and costs associated with diagnosed medication overuse headache and potential acute medication overuse in individuals with migraine

Review

作者: Doshi, Jalpa A ; Burslem, Kate ; Lipton, Richard B ; Shewale, Anand R ; Brandenburg, Jennifer A

Objective Estimate health care resource utilization and costs associated with medication overuse headache and potential acute medication overuse. Methods A retrospective analysis was conducted with Clinformatics Data Mart data (1 January 2019–31 December 2019) that included continuously enrolled commercially insured adults with migraine (International Classification of Diseases, Tenth Revision, Clinical Modification [ICD-10-CM] code G43.xxx). Medication overuse headache was defined as ≥1 inpatient or ≥2 outpatient claims with an ICD-10-CM code G44.41/40 (drug-induced headache). Potential acute medication overuse was defined as possessing sufficient medication for >10 mean treatment days/month for ergots, triptans, opioids, or combination analgesics or >15 mean cumulative days/month for simple prescription analgesics (e.g., acetaminophen, aspirin, other non-opioid analgesics) for >6 consecutive months. All-cause and migraine-related health care resource utilization and costs were compared after adjusting for demographic and clinical characteristics. Results Among 90,017 individuals with migraine, the frequency of medication overuse headache/potential acute medication overuse was 12.6% (diagnosed medication overuse headache: 0.6%; potential acute medication overuse: 12.1%). Adjusted all-cause total costs ($31,235 vs $21,486; difference: $9,749 [ P < 0.001]) and adjusted migraine-related total costs ($9,770 vs $6,207; difference: $3,563 [ P < 0.001]) were higher in the medication overuse headache/potential acute medication overuse group versus those without medication overuse headache/potential acute medication overuse. Conclusions Individuals with diagnosed medication overuse headache/potential acute medication overuse had higher all-cause and migraine-related health care resource utilization and costs versus individuals without medication overuse headache/potential acute medication overuse, suggesting that improved migraine management is needed to reduce associated costs.

2023-11-01·Nursing in Critical Care

The effect of local cold compresses for nitroglycerin‐induced headache: An observational pretest–posttest study

Article

作者: Enç, Nuray ; Uğurlu, Yasemin Kalkan

AbstractBackgroundNitroglycerin (NTG)‐induced headache is the most common side effect of nitrate therapy and negatively affects the quality of life.AimsTo assess the preventive and severity‐reducing effect of cold compresses applied to the bilateral frontotemporal and occipital regions, where pain is most frequently experienced, for headache among individuals receiving intravenous NTG treatment.Study DesignThis research used an observational, two‐group, pretest–posttest design and was completed from October 2020 to May 2021 in the coronary intensive care unit of a state hospital located in the north of Turkey. The first group in the research had cold compresses applied for 20 min with the aid of an applicator at the start of NTG infusion, while the second group had the same implementation when headache developed during infusion.ResultsBoth groups were similar in terms of the demographic and clinical features of participants. In our study, more headache was observed in the group without local cold compresses at the start of infusion (53.3%) compared with the group with local cold compresses at the start of infusion (25.8%) (χ2 = 4.841, p = .028). In both groups, the heart rate, systolic and diastolic blood pressure values of patients significantly approached normal values after cold compresses. Patients with local cold compresses applied when headache developed had significantly different visual analog scale scores before (5.75) and after (2.00) the cold compresses application (z = 3.558, p = .000).ConclusionAt the beginning of the infusion, local cold compresses application may prevent NTG‐induced headache in patients without headache, and local cold compresses applied when headache develops may reduce the severity of NTG‐induced headache.Relevance to Clinical PracticeApplication of cold compresses immediately when treatment begins is recommended as a simple and effective practice with no side effects for patients receiving NTG treatment.